Share this

KN-045

Back

References:

  1. KEYTRUDA® Prescribing Information.
  2. Bellmunt J, de Wit R, Vaughn DJ, et al, for the KEYNOTE-045 Investigators, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, Vol 376, Pages 1015–1026. Copyright © 2017 Massachusetts Medical Society.
  3. Bellmunt J, de Wit R, Vaughn DJ, et al, Supplementary for the KEYNOTE-045 Investigators, Pembrolizumab as second- line therapy for advanced urothelial carcinoma, Vol 376, Pages 1015–1026. Copyright © 2017 Massachusetts Medical Society.

References:

  1. Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol.2019;30
  2. Bellmunt J, de Wit R, Vaughn DJ, et al, for the KEYNOTE-045 Investigators, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, Vol 376, Pages 1015–1026. Copyright © 2017 Massachusetts Medical Society.

References:

  1. Balar, A. V., Castellano, D. E., Grivas, P., Vaughn, D. J., Powles, T., Vuky, J., Fradet, Y., Lee, J. & O’Donnell, P. H. (2023). Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 34(3), 289–299. https://doi.org/10.1016/j.annonc.2022.11.01
  2. Bellmunt J, de Wit R, Vaughn DJ, et al, for the KEYNOTE-045 Investigators, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, Vol 376, Pages 1015–1026. Copyright © 2017 Massachusetts Medical Society.

References:

  1. Balar, A. V., Castellano, D. E., Grivas, P., Vaughn, D. J., Powles, T., Vuky, J., Fradet, Y., Lee, J. & O’Donnell, P. H. (2023). Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 34(3), 289–299. https://doi.org/10.1016/j.annonc.2022.11.01
  2. Bellmunt J, de Wit R, Vaughn DJ, et al, for the KEYNOTE-045 Investigators, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, Vol 376, Pages 1015–1026. Copyright © 2017 Massachusetts Medical Society.

References:

  1. Balar, A. V., Castellano, D. E., Grivas, P., Vaughn, D. J., Powles, T., Vuky, J., Fradet, Y., Lee, J. & O’Donnell, P. H. (2023). Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 34(3), 289–299. https://doi.org/10.1016/j.annonc.2022.11.01
  2. Bellmunt J, de Wit R, Vaughn DJ, et al, for the KEYNOTE-045 Investigators, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, Vol 376, Pages 1015–1026. Copyright © 2017 Massachusetts Medical Society.

References:

  1. KEYTRUDA® Prescribing Information.

References:

  1. Balar, A. V., Castellano, D. E., Grivas, P., Vaughn, D. J., Powles, T., Vuky, J., Fradet, Y., Lee, J. & O’Donnell, P. H. (2023). Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 34(3), 289–299. https://doi.org/10.1016/j.annonc.2022.11.01
  2. Bellmunt J, de Wit R, Vaughn DJ, et al, for the KEYNOTE-045 Investigators, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, Vol 376, Pages 1015–1026. Copyright © 2017 Massachusetts Medical Society.

References:

  1. Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol.2019;30
  2. Balar, A. V., Castellano, D. E., Grivas, P., Vaughn, D. J., Powles, T., Vuky, J., Fradet, Y., Lee, J. & O’Donnell, P. H. (2023). Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 34(3), 289–299. https://doi.org/10.1016/j.annonc.2022.11.012.
  3. Bellmunt J, de Wit R, Vaughn DJ, et al, for the KEYNOTE-045 Investigators, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, Vol 376, Pages 1015–1026. Copyright © 2017 Massachusetts Medical Society.

KW-OMB-00004 | Exp 15 Jun 2027